Over 20 years after the “Diabetes Mellitus Insulin‐Glucose Infusion in Acute Myocardial Infarction” (DIGAMI) study, evidence for the necessity of tight glycaemic control in the immediate aftermath of AMI remains debatable.40 The DIGAMI study was primarily a trial of glucose‐insulin‐potassium (GIK) rather than glycaemic control and was predicated by the ideas that GIK may ameliorate platelet aggregation, reduce transmembrane excitability and therefore arrhythmias, and facilitate a switch in myocardial metabolism away from oxygen‐dependent fatty acid metabolism to carbohydrate metabolism. The gene discussed is INS; the disease is Arrhythmia.